Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Radiotherapy 7Brachytherapy 6Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4durvalumab 3Radiosurgery 3Methods 3tremelimumab 2aldesleukin 2Topotecan 2Radiation 2Palliative Care 2Paclitaxel 2Immunoglobulin G 2Gemcitabine 2Early Intervention, Educational 2Disulfides 2Dehydroepiandrosterone 2Counseling 2Capecitabine 2Bevacizumab 2Behavior Therapy 2Adoptive Transfer 2zimberelimab 1temsirolimus 1talazoparib 1rocakinogene sifuplasmid 1liposomal doxorubicin 1fludarabine phosphate 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Vaginal Neoplasms × MEDI0457 × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡